SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 19, 2003
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | | 0-27914 | | 34-1697351 |
(State or other jurisdiction of incorporation) | | (Commission File No.) | | (I.R.S. Employer Identification Number |
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
N/A
(Former name or former address, if changed since last report.)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE
Sirna Therapeutics, Inc. (the “Company”) announced on Friday, September 19, 2003 that Howard W. Robin, President and CEO, will present an overview of the company’s RNA interference technology and product development programs at the UBS Global Life Sciences Conference in New York City at 9:30 a.m. EDT on Wednesday, September 24, 2003. The presentation will be webcast live and may be accessed by visiting the company’s website, www.sirna.com. The presentation will be archived for 30 days.
A copy of the press release issued by the Company on Friday, September 19, 2003 is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K and the attached press release contain forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in the company’s Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
| | 99.1 | | Press Release issued by the Company on September 19, 2003. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 19, 2003
SIRNA THERAPEUTICS, INC . (Registrant) |
| |
By: | | /s/ MARVIN TANCER |
Name: | | Marvin Tancer |
Title: | | Chief Financial Officer & Vice President of Operations |
EXHIBIT INDEX
Exhibit No.
| | Description of Exhibit
|
| |
| 99.1 | | Press Release issued by the Company on September 19, 2003. |
